As Pipelines Wither, Pharma and FDA Explore Whether Microarrays are Ready for Primetime
When can the pharmaceutical industry start trusting the technology? When should it make the leap from investigative, experimental technique to industry standard? And should the FDA start using microarray data to make critical decisions about the safety and efficacy of new drugs?
Research ‘leak’ hits Genentech
Genentech’s shares dropped 12.5 per cent after details of the biotechnology company’s research abstracts for next month’s American Society of Clinical Oncology appeared to have been leaked.
As Tony White Reads Resumes, Industry Buzzes Around Core Four
It’s been two-and-a-half months since J. Craig walked away from Celera and Applera chief Tony White is still skimming resumes. Though Celera has been characteristically mum about potential prospects or their status, an initial shortlist of four likely candidates compiled by GenomeWeb from interviews with people close to the search may have evolved a bit.
President Presses Senate to Ban All Human Cloning
Declaring that “life is a creation, not a commodity,” Bush pressed the Democratic Senate to adopt legislation that would outlaw the cloning of microscopic human embryos for research into new medical therapies, in addition to outlawing the creation of cloned babies.
7 drug makers unveil elderly discounts
Under pressure from consumers and lawmakers over drug prices, Abbott Laboratories and six other manufacturers are launching a discount card for seniors that would lop 20 percent to 40 percent off the price of more than 130 commonly prescribed medicines.
Survival of fittest is new mode for biotechs
Consolidation won’t slow, and that’s no bad thing, industry watchers say
Biotech booster shot
Sector, regional economy stand to gain key ally as Harvard makes gesture to loosen its strained ties with industry
Bad Genes, Good Drugs
Wondering what happened to all that knowledge we got from mapping the human genome?
New `greenhouses’ to promote biotechnology businesses
“With fanfare that extended beyond state boundaries into prime technological turf, Pennsylvania on Wednesday began channeling $100 million to three life-sciences “greenhouses” meant to cultivate biotechnology business in the state. “
Biotech industry in race for space
“The most critical issue facing those who create and test cutting-edge drugs is finding adequate space to manufacture them.”